Zobrazeno 1 - 10
of 768
pro vyhledávání: '"Hiroshi SHIBATA"'
Publikováno v:
Frontiers in Psychology, Vol 15 (2024)
Interoception, the representation of our bodily state derived from physiological signals, is fundamental to our sense of self. Previous studies using cardiac feedback paradigms demonstrated interoceptive effects on self-perception. However, it remain
Externí odkaz:
https://doaj.org/article/a9dfd55f0f304f08848f636749445da4
Autor:
Banri Kitamura, Toshiko Iidaka, Chiaki Horii, Shigeyuki Muraki, Hiroyuki Oka, Hiroshi Kawaguchi, Kozo Nakamura, Toru Akune, Yuta Otsuka, Takayuki Izumo, Takao Tanaka, Tomohiro Rogi, Hiroshi Shibata, Sakae Tanaka, Noriko Yoshimura
Publikováno v:
Osteoarthritis and Cartilage Open, Vol 6, Iss 2, Pp 100454- (2024)
Objective: Considering the joint space width and osteophyte area (OPA) of the knee joints of Japanese adults, this study elucidated the ten-year trends in medial minimum joint space width (mJSW) and OPA using data of two independent cohorts from a po
Externí odkaz:
https://doaj.org/article/e2fafe91c995490d9e31b8bcf54cd661
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hiroshi Shibata, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 325-334 (2023)
Abstract Background/Aim A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC) in regard to progression‐free s
Externí odkaz:
https://doaj.org/article/2bbda185ed404f0a8309cd22660018ee
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Kazuya Kariyama, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Satoshi Yasuda, Atsushi Naganuma, Toshifumi Tada, Koichi Takaguchi, Akemi Tsutsui, Ei Itobayashi, Noritomo Shimada, Hiroshi Shibata, Takaaki Tanaka, Takuya Nagano, Michitaka Imai, Shinichiro Nakamura, Kazuhiro Nouso, Hisashi Kosaka, Masaki Kaibori, Takashi Kumada, Real‐life Practice Experts for HCC (RELPEC) Study Group
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 345-357 (2023)
Abstract Aims This retrospective study compared the survival between elderly and non‐elderly patients. Methods A total of 5545 treatment‐naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to Dec
Externí odkaz:
https://doaj.org/article/f81c91b804694916abe49f7211a0322c
Autor:
Yuta Otsuka, Yosuke Yamada, Akifumi Maeda, Takayuki Izumo, Tomohiro Rogi, Hiroshi Shibata, Masahiro Fukuda, Takuma Arimitsu, Naokazu Miyamoto, Takeshi Hashimoto
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 13, Iss 2, Pp 894-908 (2022)
Abstract Background A sarcopenia diagnosis is confirmed by the presence of low muscle quantity or quality under the 2018 revised definition by the European Working Group on Sarcopenia in Older People 2. Imaging methods [i.e. magnetic resonance imagin
Externí odkaz:
https://doaj.org/article/e62032abe90548feabfbdb3b74641cab
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy o
Externí odkaz:
https://doaj.org/article/1c086d02fb67435ca602adcb170580af
Autor:
Chika Horikawa, Rei Otsuka, Yukiko Nishita, Chikako Tange, Yuki Kato, Takao Tanaka, Tomohiro Rogi, Hiroshi Shibata, Fujiko Ando, Hiroshi Shimokata
Publikováno v:
BMC Geriatrics, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background There is a growing interest in the significance of adopting a variety of lifestyle habits for maintaining cognitive function among older adults. A lifestyle that is easy to modify, simple, and less burdensome for older people is i
Externí odkaz:
https://doaj.org/article/7138dd3abe834dff8f241a08668a4a91
Autor:
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract We investigated the impact on survival of modified albumin–bilirubin (mALBI) grade versus Child–Pugh classification in patients with hepatocellular carcinoma (HCC) who received lenvatinib. A total of 524 patients with HCC who received le
Externí odkaz:
https://doaj.org/article/2a6790e7eddf4f60855715ed7fd73757
Autor:
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Kazuya Kariyama, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Background/Aim: An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). M
Externí odkaz:
https://doaj.org/article/79bf22bdbb7c49b88219eb7a24df8931
Autor:
Miku Obayashi, Yasushi Shibasaki, Toru Koakutsu, Yoshiro Hayashi, Tsuyoshi Shoji, Kazuhisa Hirayama, Masanori Yamazaki, Yasuhiro Takayanagi, Hiroshi Shibata, Masato Nakamura, Hirotoshi Maruo
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Therapy targeting programmed death-1 or programmed death-1 ligand-1 (PD-1/PD-L1) has been developed for various solid malignant tumors, such as melanoma and non-small-cell lung cancer (NSCLC), but this approach has little effect i
Externí odkaz:
https://doaj.org/article/3a77ced20ce54a318496e1ad7c31944c